DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03430284

UnknownPhase 4

Multifactorial Intervention on Diabetes (MIDiab Study)

Effects of Multifactorial Intervention on Type 2 Diabetes - A Multicenter, Open-Label, Randomized, Parallel Controlled, Community Trial.

Asset

GLP-1 / incretin class catch-all

Listed sites

2

Recruiting sites

1

Enrollment

6,300

estimated

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•Integrated management rate of multiple risk factor in type 2 diabetes (HbA1c, change, Systolic BP, change, LDL-C, change, Body weight, % change)•Diabetic vascular complications•Control rate of diabetes and diabetic vascular complications

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03430284
Org study ID2017YFC1309800

Timeline

Milestones

Study first posted2018-02-12actual
Study start2018-04-01actual
Last update posted2021-07-09actual
Primary completion2021-12-31estimated
Study completion2022-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age35 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. 35-75 years old;

2. diagnosed as type 2 diabetes according to the criteria of the World Health Organization in 1999.

Exclusion criteria

1. type 1 diabetes，specific types of diabetes，gestational diabetes or pregestational diabetes;

2. acute cardiovascular or cerebrovascular accidents within past 3 months;

3. severe hepatic or renal dysfunction;

4. malignant tumor;

5. allergic history or contraindication for any drugs in trials;

6. taking part in other clinical trials;

7. obviously poor compliance.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Renal / kidney
2
Cardiometabolic biomarkers
2
Other (unclassified)
2
Cardiovascular outcomes
1
Other clinical outcomes
1

Cardiovascular outcomes

1 endpoint
Primary/protocol endpoint/low confidence

Incidence of diabetic vascular complications

Time frame:30 months

composite event, event

Renal / kidney

2 endpoints
Secondary/protocol endpoint

Urine albumin creatinine ratio (UACR)

Time frame:30 months

uACR, change

ratio, improvement

LOINC 9318-7

Secondary/protocol endpoint

Estimated glomerular filtration rate (eGFR)

Time frame:30 months

eGFR, change

change from baseline, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Carotid intima-media thickness (IMT)

Time frame:30 months

change from baseline, improvement

Secondary/protocol endpoint

Ankle brachial index (ABI)

Time frame:30 months

change from baseline, improvement

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

Stage of diabetic retinopathy evaluated by fundus photograph

Time frame:30 months

categorical status, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Integrated management rate of multiple risk factor in type 2 diabetes

Time frame:30 months

threshold achievement, improvement

componentsHbA1c, change, Systolic BP, change, LDL-C, change, Body weight, % change

Primary/protocol endpoint/low confidence

Control rate of diabetes and diabetic vascular complications

Time frame:30 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.